Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines

Bulletin Express

昨天

Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.

These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1178407621"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178407621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178407621?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178407621","market":"us","top_or_hot":-1,"title":"Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines","media":"Bulletin Express","content":"<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAb&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-13 16:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1178407621","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178407621","pubTimestamp":1763023341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"Ab&B Bio-Tech(2627)宣布开始流感疫苗I期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.\nThese vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}